Condition: Medulloblastoma · Central Nervous System Embryonal Tumor · Refractory Medulloblastoma · Sponsor: Stanford University
This is a single-site, open-label Phase 1 clinical trial evaluating the feasibility, safety, and preliminary activity of autologous GPC2-targeted chimeric antigen receptor (CAR) T cells administered via intracerebroventricular (ICV) infusion in children and young adults with relapsed or refractory medulloblastoma or other eligible Central Nervous System (CNS) embryonal tumors.
This description comes directly from the study's public registry record.
Mariah Duncan · (650) 497-8953 · GPC2CART@stanfordchildrens.org
Always discuss trial participation with your own doctor first.
| Lucile Packard Children's Hospital Stanford | Palo Alto, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07087002